1
Loftsson Thorsteinn: Cyclodextrin complexation.. Loftsson Thorsteinn, January 19, 1994: EP0579435-A1 (55 worldwide citation)

The invention provides a method for enhancing the complexation of a cyclodextrin with a lipophilic and/or water-labile drug, comprising combining from about 0.1 to about 70% (weight/volume) of a cyclodextrin and from about 0.001 to about 5% (weight/volume) of a pharmaceutically acceptable, pharmacol ...


2
Bodor Nicholas, Loftsson Thorsteinn: Transdermal delivery system.. Key Pharma, October 24, 1990: EP0393727-A2 (3 worldwide citation)

A transdermal delivery system comprising nitroglycerine and a carrier which includes 1 to 10 % by weight of oleic acid based on the weight of the carrier and preferably about 5 % by weight of oleic acid together with 50 % or more of 2-ethyl-1,3-hexanediol based on the weight of the carrier.


3
LOFTSSON THORSTEINN: Fatty acids for use as a medicament. LIPID PHARMACEUTICALS EHF, Arnason Faktor, May 6, 2010: WO/2010/049954 (3 worldwide citation)

The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as supp ...


4
Loftsson Thorsteinn, Stefansson Einar: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis Ehf, Loftsson Thorsteinn, Stefansson Einar, HEDLEY Nicholas James Matthew, February 1, 2007: WO/2007/012974 (2 worldwide citation)

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin com&rgr;lex( ...


5
Loftsson Thorsteinn, Bodor Nicholas: Systeme dadministration transdermique, Transdermal delivery system. Key Pharmaceuticals, Loftsson Thorsteinn, Bodor Nicholas, SWABEY OGILVY RENAULT, March 5, 1991: CA1280974

ABSTRACT OF THE DISCLOSURE Pharmaceutical preparations comprised of a pharmaceuticallyactive ingredient and a carrier which comprises a percutaneouspenetration enhancer comprised of 2-ethyl-1, 3-hexanediol and/oroleic acid is disclosed. The 2-ethyl-1, 3-hexanediolmay be present in an amount in the r ...


6

7
Loftsson Thorsteinn: Non-inclusion cyclodextrin complexes. Decode Genetics Ehf, August 11, 2004: EP1443969-A2

The invention provides a number of methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with beta -cyclodextrin in an aqueous complexatio ...


8
Loftsson Thorsteinn, Stefansson Einar: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis Ehf, April 16, 2008: EP1909755-A2

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin com?lex(es), ...


9
Loftsson Thorsteinn, Masson Mar: A new method. Astrazeneca, June 2, 2004: EP1423094-A2

This invention relates to a new method to improve the complexation efficacy of a basic active substance and a cyclodextrin using an acidic volatile substance. The invention further relates to a method to prepare high-energy complexes of a basic active substance and a cyclodextrin that form super-sat ...


10


Click the thumbnails below to visualize the patent trend.